1. Home
  2. ANNX vs GDOT Comparison

ANNX vs GDOT Comparison

Compare ANNX & GDOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • GDOT
  • Stock Information
  • Founded
  • ANNX 2011
  • GDOT 1999
  • Country
  • ANNX United States
  • GDOT United States
  • Employees
  • ANNX N/A
  • GDOT N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • GDOT Finance: Consumer Services
  • Sector
  • ANNX Health Care
  • GDOT Finance
  • Exchange
  • ANNX Nasdaq
  • GDOT Nasdaq
  • Market Cap
  • ANNX 362.4M
  • GDOT 363.9M
  • IPO Year
  • ANNX 2020
  • GDOT 2010
  • Fundamental
  • Price
  • ANNX $1.46
  • GDOT $7.42
  • Analyst Decision
  • ANNX Strong Buy
  • GDOT Hold
  • Analyst Count
  • ANNX 5
  • GDOT 3
  • Target Price
  • ANNX $18.67
  • GDOT $9.33
  • AVG Volume (30 Days)
  • ANNX 2.2M
  • GDOT 1.5M
  • Earning Date
  • ANNX 05-12-2025
  • GDOT 05-08-2025
  • Dividend Yield
  • ANNX N/A
  • GDOT N/A
  • EPS Growth
  • ANNX N/A
  • GDOT N/A
  • EPS
  • ANNX N/A
  • GDOT N/A
  • Revenue
  • ANNX N/A
  • GDOT $1,718,370,000.00
  • Revenue This Year
  • ANNX N/A
  • GDOT $12.61
  • Revenue Next Year
  • ANNX N/A
  • GDOT $14.11
  • P/E Ratio
  • ANNX N/A
  • GDOT N/A
  • Revenue Growth
  • ANNX N/A
  • GDOT 14.69
  • 52 Week Low
  • ANNX $1.29
  • GDOT $6.12
  • 52 Week High
  • ANNX $7.85
  • GDOT $13.58
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 30.77
  • GDOT 46.04
  • Support Level
  • ANNX $1.40
  • GDOT $7.23
  • Resistance Level
  • ANNX $1.68
  • GDOT $7.67
  • Average True Range (ATR)
  • ANNX 0.18
  • GDOT 0.49
  • MACD
  • ANNX 0.00
  • GDOT -0.03
  • Stochastic Oscillator
  • ANNX 19.13
  • GDOT 37.22

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About GDOT Green Dot Corporation $0.001 par value

Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.

Share on Social Networks: